BioNotebook: Vertex/BioAxone and four other deals; three VC updates, three public offerings
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals said in its annual report filed recently with the US Securities and Exchange Commission (SEC) that it has licensed VX-210 (formerly Cethrin) for spinal cord injuries from BioAxone Biosciences for $10m up front and up to $90m in development and regulatory milestone payments and license continuation fees.
You may also be interested in...
Finance Watch: Government Grants Galore And Other New Funding Sources
While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.